Potential Effects of Empagliflozin in L-NAME- Induced Hypertensive Nephropathy in Albino Rats
Cherry E fouqueh, Mohsen S Selim, Hisham A Awad and Dina A .Aly Labib*
Department of Medical Pharmacology, Faculty of Medicine, Cairo University, Egypt, 11952
Corresponding Author E-mail: labibd5@gmail.com
Abstract: Hypertension is the second cause of end stage renal disease (ESRD). The role of sodium-glucose transporter inhibitor (SGLTi) in hypertensive nephropathy (HN) is still unexplored. This is the first study to evaluate the potential reno-protective effects of empagliflozin, SGLT2i, alone and in combination with lisinopril in a rat model of L-NAME-induced hypertension. A total of 50 adult healthy male Sprague-Dawley albino rats were used in this study. HN was induced by using L-NAME (75 mg/kg/day) for 6 weeks. Rats were treated orally by empagliflozin alone (10 mg/kg/day), lisinopril alone (10 mg/kg/day) and a combination of both drugs with the same previously mentioned doses. Body weight (BW) and mean arterial pressure (MAP) were measured at the start, 3rd & 6th weeks of the study. Urine volume, albumin, creatinine, glucose and sodium urine levels were measured also at the start, 3rd & 6th weeks of the study. Serum creatinine, urea, sodium and potassium levels were also measured at the same timings. At the end of the study, kidney weight & renal MDA levels were assessed as well as pathological examination of the kidneys for all groups was done. Co-administration of empagliflozin with lisinopril successfully improved the biochemical & the pathological parameters in the combined group, more than either of the groups receiving each drug alone. Combination therapy of empagliflozin and lisinopril attenuated the development of renal injury than administration of either drug alone in L-NAME- induced HN in rats.
Keywords: Empagliflozin; Hypertensive; Lisinopril; L-NAME; Nephropathy Back to TOC